---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-25-000062"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:17:25.149758+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Maravai Q1 revenue $46.9M (-27% YoY), net loss $(52.9)M, adj EBITDA $(10.5)M

## Summary
- Revenue $46.9M vs $64.2M in Q1 2024; net loss $(52.9)M includes $12.4M goodwill impairment.
- Adjusted EBITDA fell to $(10.5)M from $7.8M in prior-year quarter.
- Nucleic Acid Production revenue $28.8M (-37.5% YoY) on lack of high-volume CleanCap orders; Biologics Safety Testing $18.1M (flat YoY).
- Full-year 2025 revenue guidance maintained at $185M-$205M, excluding potential high-volume CleanCap vaccine orders.
- Base business (ex CleanCap vaccine) grew >$4M sequentially from Q4 2024, per CEO Trey Martin.

## SEC filing metadata
- accession: 0001823239-25-000062
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323925000062/0001823239-25-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323925000062/mrvi-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-25-000062
- JSON: https://secwatch.observer/filing/0001823239-25-000062.json
- Plain text: https://secwatch.observer/filing/0001823239-25-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.